Ticker: GALT

Galectin Therapeutics Inc. (NASDAQ: GALT) - What's happening inside Straight to the point: the company is winding down its large NAVIGATE clinical spend, improving near‑term cash burn, but remains highly levered to related‑party financing and dependent on new capital. Clinical data are mixed - en...

Company Overview Galectin Therapeutics Inc. (NASDAQ: GALT) is a clinical stage biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer using its expertise in galectin research. The company's lead product candidate, belapectin, is being studied for treatment in p...